HIV-infected patients have metabolic abnormalities that put them at increased risk of
cardiovascular disease (CVD), including abnormalities associated with HIV infection itself …

Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. Asthis
population lives longer, coronary heart disease has become an important comorbid …

Dyslipidemia is a prevalent condition that affects patients infected with human
immunodeficiency virus (HIV) who are receiving antiretroviral therapy. These preliminary …

Dyslipidemia and lipid management in HIV-infected patients : Current Opinion in Endocrinology,
Diabetes and Obesity Dyslipidemia and lipid management in HIV-infected patients : Current …

Dyslipidemia is frequently observed in HIV-infected patients. Its pathogenesis is complex
and includes factors related to the virus, the host, and antiretroviral treatment. Dyslipidemia …

Patients infected with the human immunodeficiency virus (HIV) are prone to a great number
of lipid and lipoprotein disturbances, as a result of both the infection itself and direct effects …

Since the discovery and development of antiretroviral therapy (ART), HIV has become a
chronic disease with patients living longer lives and to ages where co‐morbidities, such as …

The availability of potent combination antiretroviral therapy has changed the long-term
prognosis for people living with HIV/AIDS. There is increasing concern, however, about the …

Dyslipidemia is a common problem affecting HIV-infected patients receiving antiretroviral
therapy. Since publication of preliminary guidelines in 2000 [1], numerous studies have …

Dyslipidemia now is recognized as a significant potential adverse event in HIV-infected
patients who are receiving antiretroviral therapy. HIV-infected persons who have …